Sherlock Biosciences is a fast growing diagnostic company developing a portfolio of rapid point-of-need nucleic acid tests for testing at people's homes and in low-resource settings. We offer custom, co-development opportunities for additional products to leading Diagnostics and Pharma companies looking for decentralized testing solutions for diagnosis and treatment monitoring.
Our CRISPR-based engineering biology assay platform, exclusively licensed from The Broad and Harvard's Wyss Institutes, enables the detection of any genetic sequences with PCR accuracy. It is fully integrated in a simple and low-cost device platform that can take many specimen types for a wide range of potential applications from infectious disease to early detection of cancer and treatment monitoring. In 2020 the company made history with the first FDA-authorized use of CRISPR technology.